JP7525855B2 - Big3-phb2相互作用阻害phb2由来ペプチドを含む乳がん治療薬 - Google Patents

Big3-phb2相互作用阻害phb2由来ペプチドを含む乳がん治療薬 Download PDF

Info

Publication number
JP7525855B2
JP7525855B2 JP2020557810A JP2020557810A JP7525855B2 JP 7525855 B2 JP7525855 B2 JP 7525855B2 JP 2020557810 A JP2020557810 A JP 2020557810A JP 2020557810 A JP2020557810 A JP 2020557810A JP 7525855 B2 JP7525855 B2 JP 7525855B2
Authority
JP
Japan
Prior art keywords
phb2
peptide
amino acid
big3
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020557810A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2020111167A5 (cg-RX-API-DMAC7.html
JPWO2020111167A1 (ja
Inventor
豊雅 片桐
哲郎 吉丸
章 大高
貴史 宮本
康秀 岡本
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oncotherapy Science Inc
Tokushima University
Original Assignee
Oncotherapy Science Inc
Tokushima University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncotherapy Science Inc, Tokushima University filed Critical Oncotherapy Science Inc
Publication of JPWO2020111167A1 publication Critical patent/JPWO2020111167A1/ja
Publication of JPWO2020111167A5 publication Critical patent/JPWO2020111167A5/ja
Priority to JP2024005446A priority Critical patent/JP7726464B2/ja
Application granted granted Critical
Publication of JP7525855B2 publication Critical patent/JP7525855B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2020557810A 2018-11-30 2019-11-28 Big3-phb2相互作用阻害phb2由来ペプチドを含む乳がん治療薬 Active JP7525855B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024005446A JP7726464B2 (ja) 2018-11-30 2024-01-17 Big3-phb2相互作用阻害phb2由来ペプチドを含む乳がん治療薬

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2018225660 2018-11-30
JP2018225660 2018-11-30
PCT/JP2019/046505 WO2020111167A1 (ja) 2018-11-30 2019-11-28 Big3-phb2相互作用阻害phb2由来ペプチドを含む乳がん治療薬

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024005446A Division JP7726464B2 (ja) 2018-11-30 2024-01-17 Big3-phb2相互作用阻害phb2由来ペプチドを含む乳がん治療薬

Publications (3)

Publication Number Publication Date
JPWO2020111167A1 JPWO2020111167A1 (ja) 2021-10-28
JPWO2020111167A5 JPWO2020111167A5 (cg-RX-API-DMAC7.html) 2022-11-21
JP7525855B2 true JP7525855B2 (ja) 2024-07-31

Family

ID=70853835

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020557810A Active JP7525855B2 (ja) 2018-11-30 2019-11-28 Big3-phb2相互作用阻害phb2由来ペプチドを含む乳がん治療薬
JP2024005446A Active JP7726464B2 (ja) 2018-11-30 2024-01-17 Big3-phb2相互作用阻害phb2由来ペプチドを含む乳がん治療薬

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024005446A Active JP7726464B2 (ja) 2018-11-30 2024-01-17 Big3-phb2相互作用阻害phb2由来ペプチドを含む乳がん治療薬

Country Status (4)

Country Link
US (3) US12595289B2 (cg-RX-API-DMAC7.html)
EP (1) EP3889264A4 (cg-RX-API-DMAC7.html)
JP (2) JP7525855B2 (cg-RX-API-DMAC7.html)
WO (1) WO2020111167A1 (cg-RX-API-DMAC7.html)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013018690A1 (ja) 2011-07-29 2013-02-07 国立大学法人徳島大学 Erap1由来ペプチド及びその使用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8516611D0 (en) 1985-07-01 1985-08-07 Du Pont Canada Fire-retardant sheet material
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
GB9201180D0 (en) 1992-01-21 1992-03-11 Glaxo Group Ltd Chemical compounds
US5804566A (en) 1993-08-26 1998-09-08 The Regents Of The University Of California Methods and devices for immunizing a host through administration of naked polynucleotides with encode allergenic peptides
US5679647A (en) 1993-08-26 1997-10-21 The Regents Of The University Of California Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides
US5739118A (en) 1994-04-01 1998-04-14 Apollon, Inc. Compositions and methods for delivery of genetic material
US5736524A (en) 1994-11-14 1998-04-07 Merck & Co.,. Inc. Polynucleotide tuberculosis vaccine
AU7335396A (en) 1995-11-01 1997-05-22 Dnavec Research Inc. Membrane-fusible liposome with the use of recombinant sendai virus
JP2000516090A (ja) 1996-07-26 2000-12-05 スローン―ケッタリング インスティチュート フォー キャンサー リサーチ 遺伝子的免疫化のための方法と試薬
AU749544B2 (en) 1998-06-25 2002-06-27 Dainippon Sumitomo Pharma Co., Ltd. Tumor antigen peptides originating in cyclophilin B
US7998695B2 (en) 2005-02-10 2011-08-16 Oncotherapy Science, Inc. Method of diagnosing bladder cancer
JP5339291B2 (ja) 2006-08-10 2013-11-13 オンコセラピー・サイエンス株式会社 乳癌に関連する遺伝子およびポリペプチド
JP6923135B2 (ja) 2016-01-19 2021-08-18 国立大学法人徳島大学 がん治療用ペプチド及びそれを含む医薬組成物
CN111148752B (zh) 2017-07-19 2024-01-16 国立大学法人德岛大学 肽衍生物和包含其的药物组合物

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013018690A1 (ja) 2011-07-29 2013-02-07 国立大学法人徳島大学 Erap1由来ペプチド及びその使用

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BMC Research Notes,2014年,Vol.7, No.435,pp.1-8
Cancer Sci.,2015年,Vol.106, No.5,pp.550-558
Nature Communications,2013年,4:2443
第41回日本分子生物学会年会 要旨集,2018年11月09日,2P-0632

Also Published As

Publication number Publication date
US20220098256A1 (en) 2022-03-31
WO2020111167A1 (ja) 2020-06-04
JP7726464B2 (ja) 2025-08-20
US20260209292A1 (en) 2026-07-23
US12595289B2 (en) 2026-04-07
EP3889264A1 (en) 2021-10-06
JPWO2020111167A1 (ja) 2021-10-28
JP2024045244A (ja) 2024-04-02
EP3889264A4 (en) 2022-10-12
US20260234205A1 (en) 2026-08-13

Similar Documents

Publication Publication Date Title
CN112119085B (zh) 稳定肽-介导的靶向蛋白降解
KR101749204B1 (ko) 올리고펩타이드 화합물 및 이의 용도
US11884708B2 (en) Stapled peptide inhibitors of nemo as potential anti-inflammatory and anti-cancer drugs
US20240075099A1 (en) COMPOSITIONS, ASSAYS, AND METHODS FOR TARGETING HDM2 AND HDMX TO REVERSE THE INHIBITION OF p53 IN PEDIATRIC CANCERS
US10087215B2 (en) Stabilized SOS1 peptides
WO2004092339A2 (en) Modulation of muc1 mediated signal transduction
US20100292145A1 (en) Methods of regulating apoptosis
WO2015063747A2 (en) Peptide inhibitors of tead/yap-taz interaction
WO2013018690A1 (ja) Erap1由来ペプチド及びその使用
IL275774A (en) Variants of ATF5 peptide and their uses
AU2007238186B2 (en) Disheveled PDZ modulators
JP2024028553A (ja) Dpep-1結合剤および使用の方法
CN101146822A (zh) EphB受体结合肽
CN115397513A (zh) 改进的抗衰老化合物及其用途
JP7726464B2 (ja) Big3-phb2相互作用阻害phb2由来ペプチドを含む乳がん治療薬
Crnković-Mertens et al. Isolation of peptides blocking the function of anti-apoptotic Livin protein
Fujiwara et al. A Cyclized Helix‐Loop‐Helix Peptide as a Molecular Scaffold for Cell‐Membrane Permeable Inhibitors for the Interaction Between Estrogen Receptor α and Coactivator SRC1
WO2025193770A1 (en) Macrocyclic peptides
Wen Development and Application of Cell Penetrating Beta-Hairpin and Alpha-Helical Peptides
Quach Investigating the Factors that Affect Trafficking of Hydrocarbon-Stapled Peptides and the Epidermal Growth Factor Receptor
Hurd Development of stapled peptides targeting
Barclay Direct Inhibition of the Conformational Activation of Pro-Apoptotic BAX by the BH4 Domain Helix of BCL-2
HK1184473A (en) Methods and compositions for modulating the wnt pathway

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20210322

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221110

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20221110

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230920

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20231031

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240117

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240304

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240422

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20240424

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240628

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240710

R150 Certificate of patent or registration of utility model

Ref document number: 7525855

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150